Application of lercanidipine in the treatment of hypertension
| Autor: | V. S Zadionchenko, G. G Shehyan, S. I Varentsov, A. A Yalymov |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
randomized clinical trials
lcsh:Diseases of the circulatory (Cardiovascular) system medicine.medical_specialty hypertension lcsh:Diseases of the endocrine glands. Clinical endocrinology law.invention Pharmacokinetics Randomized controlled trial law Internal medicine Heart rate lercanidipine lerkamen medicine dihydropyridines calcium antagonists generation iii lcsh:RC648-665 business.industry Lercanidipine medicine.disease Comorbidity Clinical trial Blood pressure Tolerability lcsh:RC666-701 Cardiology business medicine.drug |
| Zdroj: | КардиоСоматика, Vol 5, Iss 2, Pp 46-50 (2014) |
| ISSN: | 2658-5707 2221-7185 |
| DOI: | 10.26442/cs45099 |
| Popis: | The article presents data from clinical trials that have examined the efficacy and safety of modern calcium antagonist (CA) III generation of lercanidipine. The results of studies show that treatment with lercanidipine leads to a marked reduction in systolic and diastolic blood pressure without significant effect on heart rate. Unique pharmacokinetic characteristics of the drug provide its excellent efficacy and safety, good tolerability, convenience, acceptance and high adherence CA data in patients with hypertension. Additional properties of lercanidipine allow us to recommend the use of the CA in comorbidity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|